Thermo Fisher Scientific, Inc. reported unaudited consolidated earnings results for the first quarter ended March 30, 2013. For the quarter, the company reported revenues of $3,191.5 million compared to $3,056.8 million a year ago. Operating income was $387.1 million compared to $361.5 million a year ago. Income before income taxes was $342.9 million compared to $311.1 million a year ago. Income form continuing operations was $340.8 million or $0.94 per diluted share compared to $280.8 million or $0.76 per basic and diluted share a year ago. Net income was $336.2 million or $0.93 per diluted share compared to $277.3 million or $0.75 per diluted share a year ago. Adjusted operating income was $615.1 million compared to $576.5 million a year ago. Adjusted net income was $495.7 million or $1.37 per share compared to $434.4 million or $1.17 per share a year ago. Net cash provided by operating activities was $298.3 million compared to $392.0 million a year ago. Purchases of property, plant and equipment was $66.0 million compared to $69.2 million a year ago. The company revised its earnings guidance for the fiscal 2013. For the year, the company is updating its revenue guidance range from $12.80 billion to $13.00 billion to a new range of $12.84 billion to $13.00 billion, resulting in 3% to 4% growth year over year. It is also updating full year 2013 adjusted EPS guidance from $5.32 to $5.46 to a new range of $5.27 to $5.39, reflecting the suspension of share buybacks and tightening of its revenue range. This would lead to 7% to 9% growth over 2012. The 2013 guidance does not include the acquisition of Life Technologies or the impact of related financing activities. As previously stated, the guidance does not include any other future acquisitions or divestitures, and is based on current foreign exchange rates. The company expects net interest expense to be consistent with its previous guidance, and forecasting adjusted income tax rate to be in the range of 14.5% to 15%, consistent with its previous guidance. Finally, the company expects capital expenditures to be in the range of $300 million to $325 million and free cash flow to be in the range of $1.8 billion to $1.9 billion, no change from its previous guidance.

Thermo Fisher Scientific Inc. announced the Thermo Scientific TruDefender FTX analyzer, the company’s latest addition to its line of handheld FTIR chemical identification instruments. Designed for use by first responders, hazmat teams, bomb squads, military and law enforcement personnel worldwide, these analyzers feature a self-contained anvil sampling head that enables better sample control and variable pressure for enhanced safety. The new anvil mechanism is designed for improved performance and operator safety, offering the following benefits: Enables variable pressure to provide safer analysis of potentially pressure- or friction-sensitive materials; Contoured design without crevices or friction points is intended to ensure safer sampling and simplify decontamination; The anvil fully rotates for sample placement and decontamination, a key capability when operating with limited visibility and dexterity; Optional sampling accessory allows easy placement of prills and offers protection for volatile liquids; TruDefender FTX instruments are certified to MIL-STD-801G ruggedness standards and use the same field-proven algorithms and easy-to-use software as earlier TruDefender and FirstDefender Raman instruments. This minimizes training for organizations and field teams that are already familiar with the platform.

To discuss the acquisition of Life Technologies Corporation by Thermo Fisher Scientific, Inc.